<- Go Home
Zosano Pharma Corporation
On December 7, 2022, Zosano Pharma Corporation went out of business as per its Chapter 11 liquidation filing under bankruptcy. Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Market Cap
$980.00
Volume
138.0K
Cash and Equivalents
$13.5M
EBITDA
-$29.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$20.2M
Profit Margin
3063.13%
52 Week High
$24.80
52 Week Low
$0.00
Dividend
N/A
Price / Book Value
0.00
Price / Earnings
-0.00
Price / Tangible Book Value
0.00
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$30.9M
Return on Equity
192.97%
Return on Assets
-41.86
Cash and Short Term Investments
$13.5M
Debt
$6.0M
Equity
$14.1M
Revenue
$659.0K
Unlevered FCF
-$17.9M
Sector
Pharmaceuticals
Category
N/A